Pulmonary function and head lift during spontaneous recovery from pipecuronium neuromuscular block.
We have studied in seven healthy conscious volunteers the correlation between the electromyographic (EMG) and clinical criteria used to identify adequate recovery from sub-paralysing doses of pipecuronium. Pipecuronium (mean dose 1.88 (range 0.92-3.16) mg) was administered to reach a T4/T1 ratio of 0.5; full recovery to 1.0 was produced in a mean time of 25.3 (14-39) min. During recovery from neuromuscular block, we measured tidal volume, forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) negative inspiratory pressure (NIP), peak expiratory flow rate (PEFR), mid-expiratory flow rate (MEFR) and 5-s head lift. The assessments were started when the train-of-four (TOF) ratio reached 0.5 +/- 0.001 and repeated at each 0.1 +/- 0.001 increase up to a ratio of 1.0. All volunteers showed ptosis and diplopia after the first dose and difficulty in swallowing with subsequent doses. They also experienced a pleasant, relaxing sedative sensation. All could sustain head lift for 5 s at a TOF ratio of 0.5 and higher, except for one subject who could not lift his head only at a ratio of 0.5. There was a statistically significant decrease in FVC, FEV1 and PEFR with a nonsignificant decrease in other pulmonary measurements, except for NIP which only decreased significantly at a ratio of 0.5. These changes are probably of no clinical importance. All the measured respiratory variables returned to control values at a TOF ratio of 0.9.
El Mikatti
N
N
Manchester Royal Infirmary.
Wilson
A
A
Pollard
B J
BJ
Healy
T E
TE
D000328:Adult; D000762:Anesthesia Recovery Period; D004172:Diplopia / Q000139:chemically induced; D004558:Electric Stimulation; D004576:Electromyography; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008168:Lung / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009334:Neck Muscles / Q000187:drug effects; D009407:Nerve Block; D009469:Neuromuscular Junction / Q000187:drug effects*; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D017300:Pipecuronium / Q000009:adverse effects / Q000494:pharmacology*; D012129:Respiratory Function Tests; D012132:Respiratory Muscles / Q000187:drug effects; D014797:Vital Capacity / Q000187:drug effects
D017300:Pipecuronium